Hadassah

Safety Success in Hadassah AMD Stem Cell Trial Presented at International Conference

Tuesday, Dec 20 2016

Stem Cell Transplant: delivery of hESC-derived RPE cells into the sub-retinal space, through a thin cannule.

Data from the first patient cohort of the Phase I/IIa Hadassah Medical Organization clinical trial with the stem cell product, OpRegen®, aimed at slowing the progression of the advanced form of dry age-related macular degeneration (dry-AMD), was presented at the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) on Friday, December 2, 2016, in Rome, Italy.

OpRegen®, comprised of retinal pigment epithelial (RPE) cells derived from human embryonic stem cells, was developed by BioTime Inc’s subsidiary, Cell Cure Neurosciences Ltd., together with Key Developers Prof. Eyal Banin, Director of Hadassah’s Center for Retinal and Macular Degenerations and a leading investigator for this trial, and Prof. Benjamin Reubinoff, head of Hadassah’s Human Embryonic Stem Cell Research Center and Chief Scientific Officer of Cell Cure. “The cells were created without the use of animal-derived products through a proprietary directed differentiation process to produce a highly purified population of RPE cells,” explains Prof. Reubinoff.

Prof. Banin notes that OpRegen has been “administered successfully in the first cohort of patients, with no serious adverse events.” In addition, retinal imaging suggests that OpRegen RPE cells are able to engraft.

The study involves the evaluation of the safety of three different dose regiments of OpRegen. The first Phase I/IIa patient cohort received an initial targeted dose of 50,000 cells. The Data Safety Monitoring Board (DSMB), an independent group of physicians and medical experts which is closely monitoring the clinical trial, has thoroughly assessed the safety profile of the first cohort of subjects and given its recommendation that the company continue the trial with the second cohort at a higher dose of 200,000 cells.

Enrollment in the second cohort is expected to be completed by the end of 2016. Depending on the outcome of the DSMB’s review of the second patient cohort, approval to begin administering the 500,000 cell dosage to the third patient cohort could be provided early next year. In addition, BioTime reports, the first OpRegen United States clinical trial site is expected to be selected in the near future.

“We are looking forward to the opportunity to present data from the first patient cohort at ISOPT,” said Adi Mohanty, Co-Chief Executive Officer of BioTime. “OpRegen’s progress in the clinic is gaining momentum and we have already treated patients with 200,000 cell doses. It is in these higher cell dose cohorts where we believe OpRegen has the potential to demonstrate more meaningful clinical outcomes and we expect to start reporting on these data in early 2017. Our goal is to develop a treatment that can serve the millions of dry-AMD patients for whom there are currently no FDA-approved therapies.”

OpRegen had received “Fast Track” designation from the Food and Drug Administration for treatment of the advanced form of dry-AMD. Details of the trial and about a patient’s eligibility are available at https://clinicaltrials.gov/ with the following Identifier: NCT02286089 (dry-AMD).

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 14 2018

Student with MS Running the Jerusalem Marathon to Support Hadassah’s MS Program

Thanks to his physicians at the Hadassah Medical Center, Dov Guggenheim, who was diagnosed with Multiple Sclerosis (MS) in 2015, has gone from “depressed to optimistic, paralyzed to athletic, and, most important, hopeless to hopeful.”

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Texas Tropical Disease Expert Meets with Hadassah Infectious Disease Specialists

Dr. Peter Jay Hotez, renowned professor in the Departments of Pediatrics and Molecular Virology and Microbiology at Houston (Texas) Baylor College of Medicine and Dean of its National School of Tropical Medicine, met with two Hadassah Medical Organization infectious disease specialists to discuss regional cooperation in fighting tropical diseases, such as the now-infamous Zika virus and leishmaniosis, which is contracted from sand flies.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Large Hadassah Study Identifies Predictor of Greater Risk of End-Stage Renal Disease

The findings of a nationwide study of over a million and a half Israeli adolescents, conducted by researchers at the Hadassah-Hebrew University Braun School of Public Health and Community Medicine, suggest that kidney disease in childhood is associated with a significantly increased risk of end-stage renal disease (ESRD) in adulthood, even if kidney function seems normal in adolescence.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Israeli Start-up’s Algorithm Predicts Which Diabetic Patients Will Suffer Kidney Dysfunction Within One Year

The Israeli start-up Medial EarlySign has created a machine-learning-based model that has proven to identify diabetic patients who are at the highest risk for experiencing renal dysfunction within one year.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More